ClinicalTrials.gg

Program

SHR-1918

A development code. Also written as “SHR-1918 injection set” and “SHR-1918 Injection”.

In Jiangsu HengRui Medicine's pipeline, ANGPTL3. Its studies are mostly in Homozygous Familial Hypercholesterolemia · Hyperlipidemias · Hypertriglyceridemia · Hypercholesterolemia, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Dec 4, 20248 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine85 open or runningphase 3since Dec 4, 2024Jun 21, 2022Jun 2027phase 2 · NCT07308392
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-1918, phase 4, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 21, 2022First study: phase 1 study in HyperlipidemiasFirst studyNCT05432544 · 72 enrolled · China
  2. Aug 15, 2023Phase 2 study in Homozygous Familial HypercholesterolemiaNCT06009393 · 26 enrolled · China
  3. Oct 26, 2023Phase 2 study in HyperlipidemicNCT06109831 · 335 enrolled · China
  4. Dec 4, 2024Phase 3 study in Homozygous Familial HypercholesterolemiaNCT06723652 · 55 enrolled · China
  5. Aug 14, 2025Phase 2 study in Homozygous Familial HypercholesterolemiaNCT07133815 · 55 planned · China
  6. Sep 22, 2025Phase 3 study in HyperlipidemiasNCT07230730 · 900 planned · China
  7. Dec 15, 2025Phase 2 study in Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisNCT07308392 · 119 enrolled · China
  8. Feb 5, 2026Phase 3 study in HypercholesterolemiaNCT07404553 · 126 planned · China

Ahead

  1. Jun 2027Primary completion: phase 2 study in Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisNCT07308392
  2. Oct 2027Primary completion: phase 3 study in HyperlipidemiasNCT07230730
  3. Jul 2028Primary completion: phase 3 study in HypercholesterolemiaNCT07404553

TargetBeta

“ANGPTL3”the company's pipeline, read by Claude · source

Other programs on ANGPTL3

ProgramCompanyFurthest phaseStudies
VSA003rulevisirna-therapeutics-hk-limitedphase 32
EDP167ruleeddingpharm-zhuhai-co-ltdphase 23

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07404553Hypercholesterolemia · China3RecruitingJul 2028126
NCT07308392Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis · China2Active, not recruitingJun 2027119
NCT07230730Hyperlipidemias · China3RecruitingOct 2027900
NCT07133815Homozygous Familial Hypercholesterolemia · China2Not yet recruitingDec 202555
NCT06723652Homozygous Familial Hypercholesterolemia · China3CompletedAug 25, 202555
NCT06109831Hyperlipidemic · China2CompletedJul 4, 2025335
NCT06009393Homozygous Familial Hypercholesterolemia · China2CompletedJun 29, 202426
NCT05432544Hyperlipidemias · China1Active, not recruitingDec 11, 202372

How it is read

Names in the registry

  • “SHR-1918”, 6 entries
  • “SHR-1918 injection set”, 1 entry
  • “SHR-1918 Injection”, 1 entry

Codes read as this program: SHR1918.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.